BC Pharmacare approves innohep

Effective February 14, 2017, BC Pharmacare has approved innohep for the additional indication of CAT for up to 6 months. For more information, please click here.

Webinar – Healthcare in the Federal Budget and How It May Affect Patients

Webinar Information: The upcoming federal budget may contain announcements related to the way healthcare is funded in Canada, including changes to the regulation of pharmaceutical prices. Value for taxpayer money should always be the focus for government, but the need for cost-containment needs to be balanced with access to optimal healthcare innovation for patients. Key

CCSN Survey on Rituxan (Rituximab)

The purpose of this survey is to provide us with the needed insights and perspectives about the use of Rituxan (Rituximab) for the treatment of patients with Philadelphia chromosome-negative, CD20 antigen positive, B-cell precursor acute lymphoblastic leukemia in adults. Our survey is open until Monday, Feb.27, 2017, as our submission is due to pCODR on Feb. 28. Click here to complete

BioCanRx, and partners, announce funding to manufacture first made-in-Canada CAR-T cells

Development of promising engineered T cell therapy part of $11 million investment in 16 collaborative research projects in novel therapies to cure cancer OTTAWA, ON – Wednesday, February 15, 2017, 10 a.m. ET – BioCanRx, and its partners, today announced funding for 16 collaborative research projects in novel therapies to cure cancer including research aimed at developing clinical Chimeric Antigen Receptor modified T cell

National Agreement Reached between Pan-Canadian Pharmaceutical Alliance and Bristol-Myers Squibb for Immuno-Oncology Treatment OPDIVO® (nivolumab)

Decisions on public reimbursement now in hands of provincial and territorial jurisdictions MONTREAL, Feb. 10, 2017 /CNW/ – Bristol-Myers Squibb Canada Co. today announced that the company has reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the immuno-oncology treatment OPDIVO®, bringing patients with advanced, difficult-to-treat cancers closer to accessing a new treatment option.

Is 3D Mammography more effective in detecting breast cancer?

OTTAWA, Feb. 8, 2017 /CNW/ – Researchers from The Ottawa Hospital Breast Health Centre and the Ottawa Integrative Cancer Centre (OICC) have opened the Ottawa site of the Lead-In to the Tomosynthesis Mammographic Imaging Screening Trial (TMIST). The Breast Health Centre is one of three clinical trial sites to launch the Lead-In in Canada. It is expected that shortly this trial

Blog: PEI Becomes Latest Province to Sign New Healthcare Agreement

Last week, Prince Edward Island agreed to a new healthcare accord with the federal government, securing an additional $45.1 million over the next ten years. British Columbia, Alberta, Manitoba, Ontario and Quebec still remain without a new agreement. When asked about the new accord, federal Health Minister Jane Philpott stated, “They’ve got some great plans

World Cancer Day Open House

On Friday, February 3rd, CCSN opened their doors in recognition of World Cancer Day! An annual event held at the CCSN office, this years’ edition was a huge success with many people in attendance. “Friday’s Open House was a great demonstration on how so many people can be affected by cancer,“ said Kati Oliver, CCSN